網膜用薬の市場規模、シェア、成長分析、薬物クラス別、適応症別、処方別、流通チャネル別、地域別 - 産業予測 2025～2032年

網膜用薬の世界市場規模は2023年に202億米ドルと評価され、2024年の218億6,000万米ドルから2032年には410億6,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは8.2％で成長する見通しです。

網膜用薬市場は、加齢黄斑変性（AMD）、糖尿病網膜症、網膜静脈閉塞症（RVO）などの網膜疾患の世界の流行によって大きな成長を遂げており、世界で1億9,600万人以上が罹患しています。高齢化、糖尿病患者の増加、眼科診断・治療へのアクセス向上などの要因が市場開発を加速させています。市場を席巻しているのは、アフリベルセプト（Eylea）、ラニビズマブ（Lucentis）、ブロルシズマブ（Beovu）などの抗VEGF薬で、Eyleaだけで世界売上高90億米ドルを超えています。さらに、革新的な徐放性ドラッグデリバリーシステムと遺伝子治療は、患者のコンプライアンスにとって重要な注射回数を減らすことで治療アプローチに革命をもたらしています。Regenxbio社、Roche社、Kodiak Sciences社などの主要企業が、より長時間作用する先進的な治療薬や硝子体内インプラントでリードしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• バリューチェーン分析
• 規制機関
• パイプライン製品の分析
• ケーススタディ

網膜用薬市場規模：薬物クラス別& CAGR（2025-2032）

• 市場概要
• 抗VEGF薬
  • VEGF-A拮抗薬
  • 二重標的抗血管新生剤
• コルチコステロイド
  • 硝子体内インプラント
  • 注射用懸濁液
• 免疫調節薬
• 遺伝子・細胞治療
• 小分子療法
• その他の薬物クラス

網膜用薬市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 黄斑変性症
• 糖尿病網膜症
• ぶどう膜炎
• その他

網膜用薬市場規模：処方別& CAGR（2025-2032）

• 市場概要
• 注射剤（溶液、懸濁液）
• インプラント（生分解性、非生分解性）
• 目薬
• 経口錠とカプセル
• 軟膏とジェル

網膜用薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

網膜用薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Roche Holding AG（incl. Genentech）
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Allergan（AbbVie Inc.）
• Alcon Inc.
• Santen Pharmaceutical Co., Ltd.
• MeiraGTx Holdings plc
• Ocuphire Pharma, Inc.
• Kodiak Sciences Inc.
• Adverum Biotechnologies, Inc.
• Oxurion NV
• Graybug Vision, Inc.
• Clearside Biomedical, Inc.
• Outlook Therapeutics, Inc.
• Iveric Bio（acquired by Astellas Pharma）
• Sandoz（a Novartis spin-off for biosimilars）
• Coherus BioSciences, Inc.
• Biogen Inc.

結論と提言

Global Retinal Drugs Market size was valued at USD 20.20 Billion in 2023 and is poised to grow from USD 21.86 Billion in 2024 to USD 41.06 Billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The retinal drugs market is witnessing significant growth driven by the global prevalence of retinal diseases like age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO), affecting over 196 million people globally. Factors such as an aging population, rising diabetes cases, and enhanced access to ophthalmic diagnostics and treatments have amplified market development. Dominating the landscape are anti-VEGF drugs like aflibercept (Eylea), ranibizumab (Lucentis), and brolucizumab (Beovu), with Eylea alone generating over $9 billion in global sales. Additionally, innovative sustained-release drug delivery systems and gene therapy are revolutionizing treatment approaches by reducing injection frequency, which is critical for patient compliance. Key players like Regenxbio, Roche, and Kodiak Sciences are leading the charge with advanced longer-acting therapies and intravitreal implants.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Drugs Market Segments Analysis

The global Retinal Drugs market is segmented on the basis of Drug Classes, Indication, Formulation, Application, Distribution Channel and region. By Drug Classes, the market is segmented into Anti-VEGF Agents, Corticosteroids, Immunomodulators, Gene & Cell Therapies, Small Molecule Therapies, and Others. By Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others. Based on Formulation, the market is segmented into Injectables, Implants, Eye Drops, Oral Tablets/Capsules, and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Retinal Drugs Market

The expansion of the global retinal drugs market can be attributed significantly to the rising prevalence of retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). In 2020, it was reported that over 196 million individuals were affected by AMD, a number projected to reach 288 million by 2040. Additionally, nearly 188 million people suffer from diabetic retinopathy and around 16.4 million from RVO. Contributing factors such as aging populations, increased screen time, and poor dietary habits are further escalating retinal health issues, enhancing the demand for effective therapeutic interventions. As patients gain access to earlier diagnoses and treatments, there is an increasing need for innovative therapies, including anti-VEGF medications, corticosteroids, and gene therapies to address these growing health concerns.

Restraints in the Global Retinal Drugs Market

Despite advancements in retinal treatment, the exorbitant cost of retinal drugs poses a substantial hurdle to market growth, particularly in low- and middle-income nations. Anti-VEGF medications, which are regarded as a cornerstone for treating various retinal conditions, are often priced prohibitively high. For example, Lucentis can range from $1,200 to $2,000 per injection, and patients might require these injections monthly. While biosimilars like Byooviz are available at lower prices, they still remain unaffordable for many healthcare systems and patients. Long-term treatment regimens further exacerbate the financial strain, as many public healthcare systems in developing regions lack the necessary funding to support these medications, while private insurance plans often exclude coverage for retinal diseases or impose substantial copayments that deter patient compliance.

Market Trends of the Global Retinal Drugs Market

The Global Retinal Drugs market is witnessing a significant trend towards the adoption of gene therapy as a groundbreaking solution for inherited retinal diseases, particularly for conditions that lack existing therapies. Leading pharmaceutical companies are investing in advanced candidates such as Regenxbio's RGX-314 and Adverum's ADVM-022, which utilize AAV-based vectors to facilitate sustained anti-VEGF expression. Additionally, MeiraGTx is making strides in developing therapies targeting rare retinal dystrophies. Despite being in clinical or early regulatory phases, these innovative therapies hold substantial strategic value, attributed to orphan drug designations, the potential for one-time treatments, and considerable pricing leverage, thereby establishing gene therapy as a key player in the future of retinal care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Value Chain Analysis
• Regulatory Bodies
• Pipeline Product Analysis
• Case Studies

Global Retinal Drugs Market Size by Drug Classes & CAGR (2025-2032)

• Market Overview
• Anti-VEGF Agents
  • VEGF-A Antagonists
  • Dual-target Anti-angiogenic Agents
• Corticosteroids
  • Intravitreal Implants
  • Injectable Suspensions
• Immunomodulators
• Gene & Cell Therapies
• Small Molecule Therapies
• Other Drug Classes

Global Retinal Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Drugs Market Size by Formulation & CAGR (2025-2032)

• Market Overview
• Injectables (Solutions, Suspensions)
• Implants (Biodegradable, Non-biodegradable)
• Eye Drops
• Oral Tablets/Capsules
• Ointments & Gels

Global Retinal Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Retinal Drugs Market Size & CAGR (2025-2032)

• North America (Drug Classes, Indication, Formulation, Distribution Channel)
  • US
  • Canada
• Europe (Drug Classes, Indication, Formulation, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Classes, Indication, Formulation, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Classes, Indication, Formulation, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Classes, Indication, Formulation, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (incl. Genentech)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (AbbVie Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio (acquired by Astellas Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (a Novartis spin-off for biosimilars)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations